Numares Health

Executive Summary

Numares Health is a German diagnostics company that has developed AXINON, the first modular software-based system for clinical diagnostics. AXINON integrates hardware, operating system, the MGS® processor, and individual test applications across multiple therapeutic areas including cardiovascular, nephrology, transplantation, oncology, and neurology. Founded in 2008 and based in Regensburg, the company is privately held and targets the growing precision medicine market by offering a flexible, scalable platform that can be adapted to various diagnostic needs. The system aims to improve accuracy and turnaround times for complex diagnostic tests, potentially reducing healthcare costs and improving patient outcomes. While the company has not disclosed total funding or valuation, its innovative approach positions it as a player in the diagnostics space, particularly in Europe and potentially global markets. The main risks include regulatory hurdles, competition from established diagnostic platforms, and the need for clinical validation and adoption by healthcare providers.

Upcoming Catalysts (preview)

• Q3 2026CE Mark for New AXINON Test Applications in Cardiovascular or Oncology60% success
• Q2 2026Strategic Partnership with Major Hospital Network or Diagnostic Lab40% success
• Q4 2026Publication of Clinical Validation Data for Nephrology or Transplantation Indications50% success